{"disease":{"id":"resectable-locally-advanced-head-and-neck-squamous-cell-carcinoma","name":"resectable locally advanced head and neck squamous cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07379424","title":"A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":37,"lead_sponsor_name":"chen chao Professor","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}